Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Summary

This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.

Timeline

Start

2021-06-16

Primary completion

2022-12-22

Completion

2023-09-30

Drugs

Indications